Human Osteopontin, N-terminal Monoclonal Antibody
Get in touch to purchase this product
Contact our team of experts to discuss your requirementsContact our expert team
- Reference Texts
- Alicia Plumer, Hongyi Duan, Sripriya Subramaniam, F. Lee Lucas, Susan Meisfeldt, Ah-Kau Ng, Lucy Liaw. Development of Fragment Specific Osteopontin Antibodies and ELISA for Quantification in Human Metastatic Breast Cancer. BMC Cancer 2008, 8:38.
- Store at -20°C to -80°C, avoid repeat freeze- thaw
- Manufacturer Country
- 0.15M PBS
- Disease Area
- Cancer & Tumour
- determined by size-exclusion chromatography
- ELISA, WB
- Clone Number
- Immunogen / Epitope
- Recombinant full-length human Osteopontin
Sorry, no results found.
Enter the full lot number and hit enter.
The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.
Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.
Novarum™ technology transforms a smartphone into a diagnostic test reader, empowering users to read and share the results of rapid tests from the point of care. Our pioneering technology can be used by anyone, anywhere, with minimal training: connecting patients and doctors, field workers, lab researchers and primary care clinicians to specialist practices as part of a mobile eco-system.